Clinical trials: Esomeprazole, completed
Ulcer
Comparison of Esomeprazole and Famotidine for Stress Ulcer Prophylaxis in Neurosurgical Intensive Care Unit
Although stress ulcer is a complication that can cause mortality and morbidity in critical patients, there is still lack of consensus about its prophylaxis. There is also few data available from Taiwan.
- Trial name
- NCT00633035
- Testing
- esomeprazole 40 mg, famotidine 20 mg
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- Far Eastern Memorial Hospital
Gastroesophageal Reflux Disease
Evaluation of 24-Hour Intragastric pH Using Esomeprazole, Lansoprazole, and Pantoprazole in Hispanic Patients With GERD
This study will be conducted in order to determine safety and efficacy esomeprazole, lansoprazole and pantoprazole control stomach acid by measuring the stomach acid in men and women of Hispanic origin who have GERD.
- Trial name
- NCT00410592
- Testing
- Esomeprazole 40mg, Pantoprazole 40mg, Lansoprazole 30mg
- Where
- 8 sites in United States, Puerto Rico
- Volunteers
- 90 people
- Sponsor
- AstraZeneca
Heartburn
To Assess the Efficacy of Esomeprazole 40 mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole
Administration of esomeprazole 40 mg to subjects who still had heartburn after receiving rabeprazole 20 mg once daily for 4 to 8 weeks will result in statistically significant improvement of heartburn after 8-week treatment.
- Trial name
- NCT01249651
- Testing
- esomeprazole 40 mg
- Where
- China
- Volunteers
- 101 people
- Sponsor
- AstraZeneca
Dyspepsia
Proton Pump Inhibitor Treatment Stop
The purpose of this study is to determine how many chronic users of antisecretory medication can stop after a test for a bacteria associated with peptic ulcer disease. This is evaluated in a discontinuation trial.
- Trial name
- NCT00120315
- Testing
- esomeprazole, Helicobacter pylori c-13 breath test
- Where
- Denmark
- Volunteers
- 171 people
- Sponsor
- Odense University Hospital
Gastroesophageal Reflux Disease
Study Comparing the Effects of Esomeprazole Adminstered Orally and Intravenously on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD)
The purpose of this study is to examine the effects of Nexium at a dose of 40mg administered orally compared to intravenously on the maximum acid output in subjects with symptoms of Gastroesophageal reflux disease (GERD).
- Trial name
- NCT00625495
- Testing
- Esomeprazole
- Volunteers
- 60 people
- Sponsor
- AstraZeneca
Gastroesophageal Reflux Disease
Ilaprazole for the Treatment of Gastroesophageal Reflux Disease (GERD) in Chinese Patients
This study is designed to evaluate the efficacy and tolerability of ilaprazole relative to that of esomeprazole in healing erosive esophagitis and resolving accompanying symptoms of GERD.
- Trial name
- NCT02860624
- Testing
- 10 mg ilaprazole, 40mg esomeprazole
- Volunteers
- 550 people
- Sponsor
- Livzon Pharmaceutical Group Inc.
Barrett's Esophagus
Barrett's Esophagus - 315 - 3 Way Cross Over
This study evaluates PGE2 production, COX-2 enzyme activity and PCNA expression in Barrett's metaplastic tissue. All patients will have a baseline endoscopy with multiple biopsies.
- Trial name
- NCT00637988
- Testing
- Esomeprazole, Aspirin, Rofecoxib
- Volunteers
- 32 people
- Sponsor
- AstraZeneca
Healthy Participants
A Study to Assess the Effect of Itraconazole, Rifampin, and Acid-Reducing Agents on INCB161734 Pharmacokinetics When Administered Orally in Healthy Participants
This study is conducted to assess the effect of itraconazole, rifampin, and acid-reducing agents on INCB161734 pharmacokinetics when administered orally in healthy participants.
- Trial name
- NCT07018635
- Testing
- INCB161734, Itraconazole, Rifampin
- Where
- United States
- Volunteers
- 63 people, healthy volunteers welcome
- Sponsor
- Incyte Corporation
Peptic Ulcer, Gastroesophageal Reflux
S-CEI of Nexium in Paediatric Patients
To capture safety and efficacy when Nexium are administered to pediatric patients in clinical practice after launch
- Trial name
- NCT03562026
- Where
- 31 sites in Japan
- Volunteers
- 240 people
- Sponsor
- AstraZeneca
Patients With Persistent Objectified Gastroesophageal Reflux and Reflux-Associated Symptoms Despite PPI-Therapy With 40mg Esomeprazole
High Dosage Esomeprazole and Baclofen for Therapy of Gastroesophageal Reflux Disease
It has been reported that Baclofen is an appropriate tool in the therapeutic management of Gastroesophageal Reflux Disease. To objectify gastroesophageal reflux combined pH-metry/impedance monitoring was applied to patients with…
- Trial name
- NEXBAC (NCT00461604)
- Where
- Germany
- Volunteers
- 40 people
- Sponsor
- Technical University of Munich
Erosive Esophagitis
Multicenter, Randomized, Double-Blind, Double-Dummy, Parallel-Group Comparison of the Remission Rates of Once Daily Treatment With Esomeprazole 20mg and Lansoprazole 15mg for 6 Months in Patients Whose EE Has Been Healed
A study to look at the rates of remission (non re-appearance of erosive esomeprazole) when treated with esomeprazole or lansoprazole; in patients in with erosive esomeprazole (EE) that is in remission (i.e. previously healed EE).
- Trial name
- NCT00644735
- Testing
- Esomeprazole, Lansoprazole
- Volunteers
- 750 people
- Sponsor
- AstraZeneca
Achlorhydria
Study to Evaluate Effects of Food or Proton Pump Inhibitor on the Pharmacokinetics of Itraconazole in Healthy Volunteers
The aim of this study is to evaluate the effects of food or proton pump inhibitor on the pharmacokinetics of itraconazole in healthy volunteers.
- Trial name
- NCT04942652
- Testing
- Itraconazole 200 mg, Esomeprazole 40 mg
- Where
- South Korea
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Gastro Oesophageal Reflux Disease
Study Comparing Fexuprazan and Esomeprazole in Patients With Gastroesophageal Reflux Disease
The goal of this clinical trial was to evaluate the effectiveness and safety of fexuprazan 40 mg for relieving symptoms of gastroesophageal reflux disease (GERD) in adults.
- Trial name
- NCT07326904
- Testing
- Fexuprazan, Esomeprazole
- Where
- 3 sites in Indonesia
- Volunteers
- 145 people
- Sponsor
- Universitas Indonesia
Gastroesophageal Reflux Disease, Reflux, Gastroesophageal
A Study To Investigate The Effectiveness Of AH234844 (Lavoltidine) Compared With NEXIUM And Ranitidine.
Current treatment for gastroesophageal reflux disease (GERD) confirms an unmet need in patients, based on slow onset of action and an inability to provide 24-hour gastric-acid suppression.
- Trial name
- NCT00405119
- Testing
- AH23844 (lavoltidine), NEXIUM (esomeprazole), ZANTAC (ranitidine)
- Where
- 2 sites in Australia
- Volunteers
- 92 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Healthy
Safety, Tolerability, PK, PD of Escalating Single and Multiple Oral Doses of CJ-12420 in Healthy Male Subjects
The objectives of this study are: To evaluate the safety and tolerability of single and multiple oral doses of CJ-12420 in healthy male subjects.
- Trial name
- NCT01473173
- Testing
- CJ-12420, Esomeprazole 40mg
- Where
- South Korea
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- HK inno.N Corporation
Peptic Ulcer
A Comparison of Two Therapeutic Strategies for the Treatment of Aspirin-associated Peptic Ulcers
Esomeprazole plus aspirin compared with esomeprazole alone for the treatment of aspirin-related peptic ulcers.
- Trial name
- NCT01353144
- Testing
- aspirin
- Where
- 3 sites in Taiwan
- Volunteers
- 178 people
- Sponsor
- Kaohsiung Veterans General Hospital.
Gastric Ulcer
Evaluating PN 400 (VIMOVO) in Reducing Gastric Ulcers Compared to Non-steroidal Antiinflammatory Drug (NSAID) Naproxen
This study uses a randomized, double-blind, controlled design to demonstrate that PN400 (esomeprazole and naproxen) is more effective in reducing the occurrence of gastroduodenal ulcers, dyspepsia, and heartburn in subjects at…
- Trial name
- NCT00527787
- Testing
- PN400 (VIMOVO), Naproxen
- Where
- United States
- Volunteers
- 434 people
- Sponsor
- POZEN
Helicobacter Pylori Infection
Evaluation of Saccharomyces Boulardii Combined With Standard Quadruple Therapy for Eradication of Helicobacter Pylori
The eradication rate of standard quadruple therapy has become less successful due to low compliance and high resistance to the antibiotics.
- Trial name
- NCT03688828
- Testing
- Saccharomyces boulardii, Esomeprazole, Amoxicillin
- Where
- China
- Volunteers
- 360 people
- Sponsor
- Huazhong University of Science and Technology
Erosive Esophagitis, GERD
Study to Evaluate the Safety and Efficacy of CJ-12420 in Patients With Erosive Esophagitis
The purpose of this study is to investigate the optimal dose and administration methods of CJ-12420 in patients with erosive esophagitis by comparing the safety and efficacy of orally administered CJ-12420 to esomeprazole 40mg.
- Trial name
- NCT02028663
- Testing
- CJ-12420, Esomeprazole
- Where
- South Korea
- Volunteers
- 206 people
- Sponsor
- HK inno.N Corporation
Gastrointestinal Diseases
Trans GERD: Efficacy and Tolerability of Esomeprazol in Patients Under Ordinary Medical Care Conditions
Under daily routine conditions and without any intervention by the sponsor regarding the selection of subjects, diagnostic procedures, therapeutic decisions (medicinal and non- medicinal therapy, dose, duration, etc.), routine…
- Trial name
- NCT00612027
- Volunteers
- 29,586 people
- Sponsor
- AstraZeneca